6/28/23, 12:50 AM AVERT (subgroup analysis) Pathway Feedback Search Clinical Topics Home Studies AVERT (subgroup analysis) AVERT (subgroup analysis) Disease Disease Cancer-associated thrombosis Catheter-related thrombosis Trial question What is the effect of apixaban in patients with cancer and a central venous catheter? Study design Multi-center Double blinded RCT Population 217 patients Inclusion criteria: patients with cancer-initiating chemotherapy who were at intermediate-to-high risk of VTE Key exclusion criteria: lesions or conditions leading to increased risk of clinically significant bleeding; liver insufficiency; planned stem cell transplant; life expectancy < 6 months Interventions N=126 apixaban (a dose of 2.5 mg BID for 6 months) N=91 placebo (matching placebo for 6 months) Primary outcome Venous thromboembolism at 180 days 18.7 18.7 % 14.0 % 9.3 % Significant decrease 4.8 4 7 % https://web.pathway.md/studies/recpunmuJEDb44n2Q 1/2 6/28/23, 12:50 AM AVERT (subgroup analysis) Pathway 4.7 % NNT = 7 0.0 % Apixaban Placebo Significant decrease in VTE at 180 days (4.8% vs. 18.7%; HR 0.26, 95% CI 0.14 to 0.47) Secondary outcomes Significant decrease in proximal deep vein thrombosis at 180 days (3.2% vs. 12.4%; HR 0.26, 95% CI 0.12 to 0.55) Significant decrease in death at 180 days (0.8% vs. 2.2%; HR 0.35, 95% CI 0.24 to 0.49) Safety outcomes No significant differences in major bleeding, clinically relevant non-major bleeding. Conclusion In patients with cancer-initiating chemotherapy who were at intermediate-to-high risk of VTE, apixaban was superior to placebo with respect to VTE at 180 days. Reference Willem Brandt, Cameron Brown, Tzu-Fei Wang et al. Efficacy and safety of apixaban for primary prevention of thromboembolism in patients with cancer and a central venous catheter: A subgroup analysis of the AVERT Trial. Thromb Res. 2022 May 29;216:8-10. Open reference URL https://web.pathway.md/studies/recpunmuJEDb44n2Q 2/2